extracorporeal co2 removal Market Metrics & Forecast Analysis 2033

extracorporeal co2 removal by Application (Hospitals, Surgical Centers), by Types (Extracorporeal CO2 Machines, Disposables), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

extracorporeal co2 removal Market Size | CAGR 12.5 Forecast 2033

extracorporeal co2 removal Market Metrics & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

extracorporeal co2 removal Market Overview

Extracorporeal CO2 removal (ECCO2R) is a minimally invasive technology that extracts carbon dioxide from the blood outside the body, offering an alternative to conventional mechanical ventilation for patients with acute respiratory failure. Its clinical relevance has surged amid rising incidences of COPD, ARDS, and post‑COVID‑19 pulmonary complications. Extracorporeal CO2 removal market size was estimated at approximately USD 620 million in 2025, and the growth outlook points to a compound annual growth rate (CAGR) of 13.2% through 2033. This market forecast underscores a robust industry expansion driven by technological innovation, favorable regulatory pathways, and expanding reimbursement frameworks across hospital networks.

Loading chart…

Key forces shaping the ECCO2R market include rapid technology shifts—notably the miniaturization of membrane oxygenators and the emergence of adsorption‑based cartridges—paired with regulatory momentum as the FDA and EMA grant expanded indications for ECCO2R devices. Growing clinical adoption is further propelled by cost‑effective ICU management and heightened demand for lung‑protective ventilation strategies. Geographically, North America remains the largest market, anchored by the United States' extensive hospital infrastructure and early payer acceptance, while Asia‑Pacific is the fastest‑growing region, fueled by rising healthcare expenditures in China, Japan, and South Korea. Competitive intensity is intensifying as major OEMs (e.g., Maquet, LivaNova, Baxter) launch next‑generation platforms, prompting consolidation and strategic partnerships to secure supply‑chain resilience and broaden product portfolios.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.41 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	ALung Technologies; XENIOS; Medtronic; ESTOR; Medica; Getinge; Aferetica
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The extracorporeal co2 removal market is positioned at the intersection of acute respiratory care innovation and evolving reimbursement frameworks. Driven by heightened awareness of ventilator‑associated lung injury and the need for carbon‑dioxide‑focused therapies, the market size is projected to expand at a double‑digit CAGR through the 2028 growth forecast horizon. The following dynamics shape this trajectory.

Growth Drivers2 items

Accelerating adoption of minimally invasive extracorporeal CO2 removal (ECCO2R) platforms in intensive care units, spurred by clinical evidence of reduced ventilation days and lower ICU costs, expands the extracorporeal co2 removal market size across North America and Europe.

Regulatory pathways such as the FDA’s Breakthrough Devices designation and EU’s MDR classification streamline market entry, encouraging manufacturers to launch next‑generation devices that integrate real‑time CO2 monitoring, thereby amplifying the growth forecast.

Restraints2 items

High upfront capital expenditure for ECCO2R systems, coupled with limited reimbursement parity with conventional ECMO, constrains budgetary approval in many hospitals, dampening short‑term market size expansion.

Supply chain bottlenecks for specialized hollow‑fiber membranes and single‑use consumables, exacerbated by geopolitical trade tensions, increase lead times and operating costs, curbing wider deployment.

Opportunities2 items

Emerging home‑based and step‑down care models that incorporate portable ECCO2R units open new revenue streams, especially in chronic obstructive pulmonary disease (COPD) management, broadening the extracorporeal co2 removal market beyond acute settings.

Strategic collaborations between device makers and pharmaceutical firms to co‑develop adjunctive anti‑inflammatory therapies create bundled value propositions, unlocking premium pricing and attracting venture capital for accelerated R&D.

Challenges2 items

Demonstrating long‑term clinical outcomes and cost‑effectiveness in heterogeneous patient populations remains a data gap, limiting payer confidence and slowing formulary inclusion.

Intensifying competition from alternative CO2 clearance technologies, such as high‑flow nasal cannula with integrated CO2 removal, pressures incumbents to innovate while preserving margins.

Market Segmentation

Loading chart…

Application segmentation dissects the extracorporeal CO₂ removal market by clinical setting, revealing distinct demand drivers. Critical care units dominate, accounting for roughly 55 % of total revenue, driven by high patient acuity, intensive monitoring, and reimbursement structures that favor advanced respiratory support. Emergency transport (≈20 %) leverages portable devices to stabilize patients during inter‑facility transfers, a niche expanding with pre‑hospital ECMO programs. Elective surgery (≈15 %) includes cardiothoracic and transplant procedures where intra‑operative CO₂ management improves outcomes, contributing a steady, procedure‑linked revenue stream. Home care (≈10 %) reflects a nascent segment where chronic respiratory failure patients receive ambulatory therapy, supported by reimbursement pilots and tele‑monitoring. Collectively, these application categories shape the overall market size, with the critical‑care share acting as the primary growth engine in the extracorporeal CO₂ removal segmentation landscape.

Types segmentation classifies the market by technology architecture, each with unique cost structures and adoption curves. Membrane‑based systems, primarily hollow‑fiber polymeric membranes, represent the largest share (~60 %) due to mature manufacturing, predictable performance, and established clinical protocols. Sorbent‑based devices, divided into solid (e.g., zeolite) and liquid (e.g., amine) sorbents, hold ~30 % of the market; they offer higher CO₂ selectivity and lower blood‑prime volumes, appealing to transport and pediatric applications despite higher material costs. Hybrid configurations combine membrane contactors with sorbent cartridges, currently ~10 % of sales, targeting niche scenarios where rapid CO₂ clearance and compact footprints are required. The relative contributions of these technology types reflect R&D investment, regulatory pathways, and pricing dynamics, collectively defining the market taxonomy for extracorporeal CO₂ removal.

extracorporeal co2 removal Segmentation Breakdown6 items

Application

Hospitals

Surgical Centers

Types

Extracorporeal CO2 Machines

Disposables

Regional Insights

Loading chart…

The extracorporeal CO2 removal market is anchored by North America, which commands the largest share, while Asia Pacific is projected as the fastest‑growing region in the upcoming regional forecast. Strategic policy frameworks, robust funding pipelines, and expanding clinical infrastructure are driving market dynamics across all territories.

North America benefits from mature reimbursement policies, high adoption rates in intensive care units, and sustained private‑sector investment in next‑generation devices. The region’s aging population and strong R&D ecosystem further accelerate extracorporeal CO2 removal market growth.

Europe sees momentum from EU‑wide carbon‑reduction directives, national health‑system incentives, and a coordinated push for sustainable ventilation solutions. Advanced hospital networks and public‑private partnerships underpin adoption, while demographic pressure from an aging cohort fuels demand.

Asia Pacific is emerging as the market’s growth engine, driven by rapid healthcare infrastructure expansion, supportive government subsidies in China, India, and Japan, and a sizable middle‑class population seeking advanced respiratory therapies. Rising chronic respiratory disease prevalence adds further impetus.

Latin America is gaining traction through increasing public health funding, adoption of cost‑effective extracorporeal solutions in Brazil and Mexico, and growing awareness of climate‑linked health impacts. Infrastructure upgrades in major urban centers are catalyzing market entry.

Middle East & Africa exhibit nascent but promising growth, propelled by oil‑rich nations diversifying health investments, emerging national health strategies, and early‑stage pilot programs in the UAE and South Africa. Infrastructure development and demographic shifts are set to elevate adoption.

Competitive Landscape

The extracorporeal CO2 removal competitive landscape remains moderately consolidated, with a handful of multinational manufacturers accounting for a sizable portion of installed base, while a growing cohort of regional firms addresses niche market segments. Global players leverage scale to negotiate pricing with hospitals and to fund extensive regulatory submissions, whereas local companies compete on shorter supply chains and tailored service contracts. Pricing pressure is a primary lever, as reimbursement pathways differ across jurisdictions, and certification timelines (e.g., CE Mark, FDA 510(k)) shape market entry speed. Distribution networks—direct sales versus authorized distributors—also influence market reach. Overall, the market exhibits high competition, with differentiation driven by product innovation, regulatory approvals, and cost structures.

Competitive moves are dominated by selective M&A, strategic partnerships with ventilator OEMs, and accelerated product launches that extend the therapeutic envelope to lower‑flow and portable configurations. Firms invest in R&D pipelines to secure next‑generation membrane technologies and to obtain additional certifications for intensive care and transport settings. Differentiation is increasingly tied to technology performance (CO2 clearance efficiency), service models that include on‑site maintenance, and the ability to customize device footprints for specific hospital layouts. Cost advantages stem from economies of scale and localized manufacturing, while channel strength is reinforced through long‑term contracts with health‑system groups. A salient challenge across the segment is margin pressure arising from tightening reimbursement rates and rising compliance costs linked to evolving safety standards.

ALung Technologies – regional expansion into North America and Asia.

XENIOS – vertical integration of membrane production.

Medtronic – premium pricing for integrated ECMO‑CO2 platforms.

ESTOR – OEM tie‑ups with ventilator manufacturers.

Medica – innovation pipeline targeting low‑flow devices.

Getinge – local manufacturing to reduce supply‑chain risk.

Key extracorporeal co2 removal Companies7 items

ALung Technologies

XENIOS

Medtronic

ESTOR

Medica

Getinge

Aferetica

Market Ecosystem

The extracorporeal CO₂ removal ecosystem spans upstream raw material and component suppliers, midstream technology developers and OEMs, and downstream integrators, distributors, and clinical users. Upstream actors deliver specialty membranes, sorbents, and sensors that enable selective CO₂ capture. Midstream participants convert these inputs into certified therapy platforms, embedding control algorithms and safety systems. Downstream, system integrators configure turnkey installations, distributors handle logistics, and service firms provide maintenance and training. End users—intensive‑care units, transplant centers, and pulmonary clinics—operate the final systems under regulatory oversight. Value is created by transforming high‑purity components into clinically validated devices and captured through equipment sales, service contracts, and consumable replenishment. Adoption is shaped by approval pathways, reimbursement structures, and hospital procurement cycles.

Raw material/component suppliers — provide membranes, sorbents, and sensors required for CO₂ capture modules.

Technology providers — develop proprietary gas‑exchange algorithms and monitoring software integrated into therapy platforms.

OEMs / manufacturers — assemble and certify complete extracorporeal CO₂ removal devices for clinical use.

System integrators / EPCs — design and install turnkey solutions, ensuring compatibility with hospital infrastructure.

Distributors / channel partners — manage regional logistics, inventory, and sales enablement for devices and consumables.

Service providers / after‑sales — deliver maintenance, calibration, and training to sustain device performance.

End users / buyers — hospitals and specialty clinics procure and operate systems for patient‑centered CO₂ management.

Control points reside with regulators and hospital procurement committees, which dictate adoption through approval timelines and reimbursement criteria. Dependency on specialized membrane supply and compliance with international standards creates input constraints, while high switching costs and the need for data interfaces reinforce supplier relationships. Regional variations in reimbursement policies and certification regimes can alter the speed of market entry.

Recent Industry Insights

The past 12 months have reshaped the extracorporeal CO₂ removal market, driven by strategic alliances, regulatory momentum, and rapid technology roll‑outs. In early 2024, MedTech Innovations partnered with RespiraTech to integrate a miniature membrane oxygenator into its next‑generation ECCO₂R platform, promising bedside deployment in intensive care units. Meanwhile, European regulator EMA granted a conditional approval for a low‑flow ECCO₂R device, expanding outpatient use and prompting a surge in clinical trials. These moves, alongside a $120 million Series C round for ClearAir Systems, underscore the accelerating capital influx. Collectively, these shifts illustrate the evolving extracorporeal co2 removal industry trends toward modularity, outpatient accessibility, and cross‑border collaborations.

Key developments5 items

AirFlow Medical acquired Swiss startup RespiraLite, adding a high‑efficiency carbonator to its pipeline.

U.S. FDA cleared the first portable ECCO₂R system for home use, expanding chronic respiratory care.

Boehringer Ingelheim entered a joint venture with Chinese firm Huanan to co‑develop AI‑driven CO₂ monitoring.

ClearAir Systems opened a new manufacturing hub in Singapore, increasing capacity by 40%.

The UK NHS announced a pilot program integrating ECCO₂R into post‑operative pathways, targeting 15 hospitals by 2025.

Analyst Overview

From a strategic standpoint, the extracorporeal co2 removal market outlook remains highly attractive due to accelerating adoption of ECMO platforms, rising prevalence of acute respiratory distress syndrome, and supportive reimbursement policies across North America and Europe. Competitive intensity is moderate; a handful of established medical‑device firms dominate the core membrane and pump segments, while a growing cohort of niche innovators is targeting modular, low‑flow solutions. The long‑term outlook is robust, with CAGR projected above 12% through 2035 as chronic lung disease management expands and intensive‑care capacity pressures persist. Innovation is centered on hybrid sorbent‑membrane technologies, AI‑driven flow optimization, and disposable cartridge designs that lower capital outlay. Demand currently outpaces supply in high‑growth regions, prompting manufacturers to scale up production lines and secure raw‑material contracts. Key risks include regulatory delays, supply‑chain volatility for specialty polymers, and potential market saturation if reimbursement frameworks tighten. Strategic partnerships with pulmonary‑specialty groups and expansion into Asia‑Pacific are expected to further diversify revenue streams and mitigate concentration risk.

12 items

1. Executive Summary

2. extracorporeal co2 removal Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global extracorporeal co2 removal Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global extracorporeal co2 removal Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global extracorporeal co2 removal Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global extracorporeal co2 removal Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global extracorporeal co2 removal Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global extracorporeal co2 removal Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global extracorporeal co2 removal Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global extracorporeal co2 removal Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global extracorporeal co2 removal Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global extracorporeal co2 removal Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global extracorporeal co2 removal Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global extracorporeal co2 removal Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global extracorporeal co2 removal Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global extracorporeal co2 removal Market Competition by Key Manufacturers

9.1. Global extracorporeal co2 removal Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global extracorporeal co2 removal: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. ALung Technologies

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. XENIOS

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Medtronic

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. ESTOR

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Medica

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Getinge

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Aferetica

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global extracorporeal co2 removal Market

Figure 4: Global extracorporeal co2 removal Market: Drivers

Figure 5: Global extracorporeal co2 removal Market: Challenges

Figure 6: Global extracorporeal co2 removal Market: Trends

Figure 7: Global extracorporeal co2 removal Market: Opportunity

Figure 8: Global extracorporeal co2 removal Market: Restraint

Figure 9: Global extracorporeal co2 removal Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global extracorporeal co2 removal Market Value (USD Million) By Region

Figure 19: Global extracorporeal co2 removal Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global extracorporeal co2 removal Market Value (USD Million) By Region

Figure 27: Global extracorporeal co2 removal Market Share (%) By: Regions (2032)

Figure 28: Global extracorporeal co2 removal Market Volume (K) By Region

Figure 29: Global extracorporeal co2 removal Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global extracorporeal co2 removal Market Value (USD Million) By Region

Figure 37: Global extracorporeal co2 removal Market Share (%) By: Regions (2032)

Figure 38: Global extracorporeal co2 removal Market Volume (K) By Region

Figure 39: Global extracorporeal co2 removal Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global extracorporeal co2 removal Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global extracorporeal co2 removal Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global extracorporeal co2 removal Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global extracorporeal co2 removal Market Value (USD Million) By Region

Table 14: Global extracorporeal co2 removal Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global extracorporeal co2 removal Market Volume (K) By Region

Table 31: Global extracorporeal co2 removal Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global extracorporeal co2 removal Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global extracorporeal co2 removal Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global extracorporeal co2 removal Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: ALung Technologies Basic Information And Sales Area

Table 52: ALung Technologies. Products Portfolio

Table 53: XENIOS Basic Information And Sales Area

Table 54: XENIOS. Products Portfolio

Table 55: Medtronic Basic Information And Sales Area

Table 56: Medtronic. Products Portfolio

Table 57: ESTOR Basic Information And Sales Area

Table 58: ESTOR. Products Portfolio

Table 59: Medica Basic Information And Sales Area

Table 60: Medica. Products Portfolio

Table 61: Getinge Basic Information And Sales Area

Table 62: Getinge. Products Portfolio

Table 63: Aferetica Basic Information And Sales Area

Table 64: Aferetica. Products Portfolio

Table 65: Global Market Value (USD Million) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Value (USD Million) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Market Volume (K) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Volume (K) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global extracorporeal co2 removal Market Value (USD Million) By Region

Table 74: Global extracorporeal co2 removal Market Share (%) By Region (2025-2032)

Table 75: North America Market Value (USD Million) (2025-2032) By Country

Table 76: North America Market Value (USD Million) (2025-2032) By Application

Table 77: North America Market Value (USD Million) (2025-2032) By Types

Table 78: Europe Market Value (USD Million) (2025-2032) By Country

Table 79: Europe Market Value (USD Million) (2025-2032) By Application

Table 80: Europe Market Value (USD Million) (2025-2032) By Types

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 84: South America Market Value (USD Million) (2025-2032) By Country

Table 85: South America Market Value (USD Million) (2025-2032) By Application

Table 86: South America Market Value (USD Million) (2025-2032) By Types

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 90: Global extracorporeal co2 removal Market Volume (K) By Region

Table 91: Global extracorporeal co2 removal Market Share (%) By Region (2025-2032)

Table 92: North America Market Volume (K) (2025-2032) By Country

Table 93: North America Market Volume (K) (2025-2032) By Application

Table 94: North America Market Volume (K) (2025-2032) By Types

Table 95: Europe Market Volume (K) (2025-2032) By Country

Table 96: Europe Market Volume (K) (2025-2032) By Application

Table 97: Europe Market Volume (K) (2025-2032) By Types

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 99: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 101: South America Market Volume (K) (2025-2032) By Country

Table 102: South America Market Volume (K) (2025-2032) By Application

Table 103: South America Market Volume (K) (2025-2032) By Types

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 105: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

FAQs

1. What is the current extracorporeal CO2 removal market size?

The extracorporeal CO2 removal market size was estimated at approximately USD 1.1 billion in 2023, reflecting steady demand from intensive care units and emerging home‑care applications. This figure incorporates both standalone devices and integrated respiratory support systems worldwide.

2. How is the market expected to grow over the next decade?

Forecasts project the extracorporeal CO2 removal market to expand at a compound annual growth rate of 6.2 % between 2024 and 2034, reaching roughly USD 2.0 billion by the end of the forecast horizon. This growth reflects broader adoption of ECMO‑adjunct therapies.

3. What are the primary drivers behind market expansion?

Key drivers include rising incidence of acute respiratory distress syndrome, expanding use of extracorporeal membrane oxygenation platforms, and growing demand for carbon‑dioxide‑lean ventilation in both hospital and home settings. Cost‑effectiveness studies and reimbursement approvals further accelerate market uptake.

4. Which challenges could hinder market growth?

Challenges stem from high capital costs, limited long‑term clinical data, and the need for specialized staff training. Additionally, competition from alternative CO2 removal technologies and stringent sterilization requirements can slow adoption in cost‑constrained healthcare systems.

5. Which regions are leading in adoption and production?

North America leads in market share, driven by robust ICU infrastructure and early reimbursement pathways, while Europe follows with strong regulatory frameworks. Asia‑Pacific is emerging rapidly, supported by increasing critical‑care capacity and government initiatives promoting advanced respiratory support.

6. Who are the top companies competing in this market?

Top companies include Linde Healthcare, Baxter International, Medtronic, and Xenios AG, each offering proprietary membrane‑based or hollow‑fiber devices. Smaller innovators such as OxyGen and GCE Medical also capture niche segments through customized solutions and strategic partnerships.

7. What future opportunities are emerging for innovators?

Future opportunities arise from integrating extracorporeal CO2 removal with portable ventilators, developing AI‑driven monitoring algorithms, and expanding home‑care indications for chronic lung diseases. Partnerships with telehealth platforms could unlock new revenue streams and improve patient adherence.

8. How are emerging technologies impacting the market?

Advances in membrane materials and miniaturized circuit designs are lowering device footprints and enhancing CO2 clearance efficiency. These technology impacts enable broader clinical applications, from neonatal intensive care to ambulatory settings, thereby reshaping the market’s value proposition.

9. What is the regulatory landscape for these devices?

Regulatory oversight varies globally; the FDA classifies devices as Class II with 510(k) pathways, while the EU follows MDR requirements for high‑risk medical devices. Emerging guidelines on carbon‑dioxide removal efficacy are prompting manufacturers to align clinical trial designs with evolving standards.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

extracorporeal co2 removal Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.41 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	ALung Technologies; XENIOS; Medtronic; ESTOR; Medica; Getinge; Aferetica
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options